Managing the Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients on Oral Anticoagulation

In patients on chronic oral anticoagulation (OAC) who are undergoing a percutaneous coronary intervention (PCI), dual antiplatelet therapy (aspirin and a P2Y12 inhibitor) is required. However, combining dual antiplatelet therapy with OAC increases the risk of bleeding. Newer and stronger P2Y12 inhib...

Full description

Saved in:
Bibliographic Details
Published in:Interventional cardiology (London) 2015-09, Vol.10 (3), p.139-141
Main Authors: Arishta Jhagroe, Darshni, Maria Ten Berg, Jurriën
Format: Article
Language:English
Subjects:
Coronary
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 141
container_issue 3
container_start_page 139
container_title Interventional cardiology (London)
container_volume 10
creator Arishta Jhagroe, Darshni
Maria Ten Berg, Jurriën
description In patients on chronic oral anticoagulation (OAC) who are undergoing a percutaneous coronary intervention (PCI), dual antiplatelet therapy (aspirin and a P2Y12 inhibitor) is required. However, combining dual antiplatelet therapy with OAC increases the risk of bleeding. Newer and stronger P2Y12 inhibitors also add more complexity to the regimen, as these antiplatelet agents are currently recommended as standard treatment in patients with acute coronary syndromes (ACS). It remains unclear whether these ACS patients on chronic OAC undergoing PCI should be treated with these new P2Y12 inhibitors as part of the antiplatelet therapy. Another issue to address is that new non-vitamin K oral anticoagulants have emerged as possible alternatives for stroke prevention in patients with AF. Thus, the anticoagulated patient undergoing PCI faces a treatment dilemma. Based on a real-life case, we will discuss the optimal anticoagulant and antiplatelet treatment with a review of the literature.
doi_str_mv 10.15420/ICR.2015.10.03.139
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5808618</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2019472933</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2709-5a16a9c3cb7c8fe0d64ba466912ead9cfb877bd9c1025e9b6402e706a0b677013</originalsourceid><addsrcrecordid>eNpVUU1LAzEUDKKoqL9AkBy9tL4km2RzEUrxo6AooueQTbNtZJvUZFfw35taFT3lfcxMhjcInRIYE15RuJhNn8YUCB-XCbAxYWoHHRLJxYhUUu7-qQ_QSc6vAECU4Kym--iAKl7XQsEhWt-bYBY-LHC_dHgSet8vU1w1sfcWPy9dMusPPGl7l_CjS3boTXBxyHgaUwwmfeBZKLt3V4gxYB_wo-l96TIu7UMy3ZemjWYxdGaDOUZ7remyO_l-j9DL9dXz9HZ093Azm07uRpZKUCNuiDDKMttIW7cO5qJqTCWEItSZubJtU0vZlIIA5U41ogLqJAgDjZASCDtCl1vd9dCs3NwWT8WNXie_KrZ1NF7_3wS_1Iv4rnkNtSB1ETj_FkjxbXC51yufreu67QV0Ob6qJFWMFSjbQm2KOSfX_n5DQH_FpUtcGwbfTIDpEldhnf11-Mv5CYd9Ai9Ik8I</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2019472933</pqid></control><display><type>article</type><title>Managing the Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients on Oral Anticoagulation</title><source>PubMed Central</source><creator>Arishta Jhagroe, Darshni ; Maria Ten Berg, Jurriën</creator><creatorcontrib>Arishta Jhagroe, Darshni ; Maria Ten Berg, Jurriën ; St Antonius Hospital, Nieuwegein, The Netherlands</creatorcontrib><description>In patients on chronic oral anticoagulation (OAC) who are undergoing a percutaneous coronary intervention (PCI), dual antiplatelet therapy (aspirin and a P2Y12 inhibitor) is required. However, combining dual antiplatelet therapy with OAC increases the risk of bleeding. Newer and stronger P2Y12 inhibitors also add more complexity to the regimen, as these antiplatelet agents are currently recommended as standard treatment in patients with acute coronary syndromes (ACS). It remains unclear whether these ACS patients on chronic OAC undergoing PCI should be treated with these new P2Y12 inhibitors as part of the antiplatelet therapy. Another issue to address is that new non-vitamin K oral anticoagulants have emerged as possible alternatives for stroke prevention in patients with AF. Thus, the anticoagulated patient undergoing PCI faces a treatment dilemma. Based on a real-life case, we will discuss the optimal anticoagulant and antiplatelet treatment with a review of the literature.</description><identifier>ISSN: 1756-1477</identifier><identifier>EISSN: 1756-1477</identifier><identifier>DOI: 10.15420/ICR.2015.10.03.139</identifier><identifier>PMID: 29588690</identifier><language>eng</language><publisher>England: Radcliffe Cardiology</publisher><subject>Coronary</subject><ispartof>Interventional cardiology (London), 2015-09, Vol.10 (3), p.139-141</ispartof><rights>Copyright © 2015, Radcliffe Cardiology</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808618/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808618/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29588690$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Arishta Jhagroe, Darshni</creatorcontrib><creatorcontrib>Maria Ten Berg, Jurriën</creatorcontrib><creatorcontrib>St Antonius Hospital, Nieuwegein, The Netherlands</creatorcontrib><title>Managing the Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients on Oral Anticoagulation</title><title>Interventional cardiology (London)</title><addtitle>Interv Cardiol</addtitle><description>In patients on chronic oral anticoagulation (OAC) who are undergoing a percutaneous coronary intervention (PCI), dual antiplatelet therapy (aspirin and a P2Y12 inhibitor) is required. However, combining dual antiplatelet therapy with OAC increases the risk of bleeding. Newer and stronger P2Y12 inhibitors also add more complexity to the regimen, as these antiplatelet agents are currently recommended as standard treatment in patients with acute coronary syndromes (ACS). It remains unclear whether these ACS patients on chronic OAC undergoing PCI should be treated with these new P2Y12 inhibitors as part of the antiplatelet therapy. Another issue to address is that new non-vitamin K oral anticoagulants have emerged as possible alternatives for stroke prevention in patients with AF. Thus, the anticoagulated patient undergoing PCI faces a treatment dilemma. Based on a real-life case, we will discuss the optimal anticoagulant and antiplatelet treatment with a review of the literature.</description><subject>Coronary</subject><issn>1756-1477</issn><issn>1756-1477</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNpVUU1LAzEUDKKoqL9AkBy9tL4km2RzEUrxo6AooueQTbNtZJvUZFfw35taFT3lfcxMhjcInRIYE15RuJhNn8YUCB-XCbAxYWoHHRLJxYhUUu7-qQ_QSc6vAECU4Kym--iAKl7XQsEhWt-bYBY-LHC_dHgSet8vU1w1sfcWPy9dMusPPGl7l_CjS3boTXBxyHgaUwwmfeBZKLt3V4gxYB_wo-l96TIu7UMy3ZemjWYxdGaDOUZ7remyO_l-j9DL9dXz9HZ093Azm07uRpZKUCNuiDDKMttIW7cO5qJqTCWEItSZubJtU0vZlIIA5U41ogLqJAgDjZASCDtCl1vd9dCs3NwWT8WNXie_KrZ1NF7_3wS_1Iv4rnkNtSB1ETj_FkjxbXC51yufreu67QV0Ob6qJFWMFSjbQm2KOSfX_n5DQH_FpUtcGwbfTIDpEldhnf11-Mv5CYd9Ai9Ik8I</recordid><startdate>20150901</startdate><enddate>20150901</enddate><creator>Arishta Jhagroe, Darshni</creator><creator>Maria Ten Berg, Jurriën</creator><general>Radcliffe Cardiology</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20150901</creationdate><title>Managing the Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients on Oral Anticoagulation</title><author>Arishta Jhagroe, Darshni ; Maria Ten Berg, Jurriën</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2709-5a16a9c3cb7c8fe0d64ba466912ead9cfb877bd9c1025e9b6402e706a0b677013</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Coronary</topic><toplevel>online_resources</toplevel><creatorcontrib>Arishta Jhagroe, Darshni</creatorcontrib><creatorcontrib>Maria Ten Berg, Jurriën</creatorcontrib><creatorcontrib>St Antonius Hospital, Nieuwegein, The Netherlands</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Interventional cardiology (London)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Arishta Jhagroe, Darshni</au><au>Maria Ten Berg, Jurriën</au><aucorp>St Antonius Hospital, Nieuwegein, The Netherlands</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Managing the Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients on Oral Anticoagulation</atitle><jtitle>Interventional cardiology (London)</jtitle><addtitle>Interv Cardiol</addtitle><date>2015-09-01</date><risdate>2015</risdate><volume>10</volume><issue>3</issue><spage>139</spage><epage>141</epage><pages>139-141</pages><issn>1756-1477</issn><eissn>1756-1477</eissn><abstract>In patients on chronic oral anticoagulation (OAC) who are undergoing a percutaneous coronary intervention (PCI), dual antiplatelet therapy (aspirin and a P2Y12 inhibitor) is required. However, combining dual antiplatelet therapy with OAC increases the risk of bleeding. Newer and stronger P2Y12 inhibitors also add more complexity to the regimen, as these antiplatelet agents are currently recommended as standard treatment in patients with acute coronary syndromes (ACS). It remains unclear whether these ACS patients on chronic OAC undergoing PCI should be treated with these new P2Y12 inhibitors as part of the antiplatelet therapy. Another issue to address is that new non-vitamin K oral anticoagulants have emerged as possible alternatives for stroke prevention in patients with AF. Thus, the anticoagulated patient undergoing PCI faces a treatment dilemma. Based on a real-life case, we will discuss the optimal anticoagulant and antiplatelet treatment with a review of the literature.</abstract><cop>England</cop><pub>Radcliffe Cardiology</pub><pmid>29588690</pmid><doi>10.15420/ICR.2015.10.03.139</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1756-1477
ispartof Interventional cardiology (London), 2015-09, Vol.10 (3), p.139-141
issn 1756-1477
1756-1477
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5808618
source PubMed Central
subjects Coronary
title Managing the Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients on Oral Anticoagulation
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T08%3A17%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Managing%20the%20Antithrombotic%20Therapy%20After%20Percutaneous%20Coronary%20Intervention%20in%20Patients%20on%20Oral%20Anticoagulation&rft.jtitle=Interventional%20cardiology%20(London)&rft.au=Arishta%20Jhagroe,%20Darshni&rft.aucorp=St%20Antonius%20Hospital,%20Nieuwegein,%20The%20Netherlands&rft.date=2015-09-01&rft.volume=10&rft.issue=3&rft.spage=139&rft.epage=141&rft.pages=139-141&rft.issn=1756-1477&rft.eissn=1756-1477&rft_id=info:doi/10.15420/ICR.2015.10.03.139&rft_dat=%3Cproquest_pubme%3E2019472933%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2709-5a16a9c3cb7c8fe0d64ba466912ead9cfb877bd9c1025e9b6402e706a0b677013%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2019472933&rft_id=info:pmid/29588690&rfr_iscdi=true